Yuka Isozaki

ORCID: 0000-0002-5395-708X
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Radiation Therapy and Dosimetry
  • Pancreatic and Hepatic Oncology Research
  • Advanced Radiotherapy Techniques
  • MicroRNA in disease regulation
  • Lung Cancer Diagnosis and Treatment
  • Esophageal and GI Pathology
  • Esophageal Cancer Research and Treatment
  • Gastrointestinal disorders and treatments
  • Colorectal Cancer Surgical Treatments
  • Gastrointestinal Tumor Research and Treatment
  • Circular RNAs in diseases
  • Hepatocellular Carcinoma Treatment and Prognosis
  • Gastroesophageal reflux and treatments
  • Cancer Research and Treatments
  • Gastric Cancer Management and Outcomes
  • RNA modifications and cancer
  • Effects of Radiation Exposure
  • Colorectal and Anal Carcinomas
  • Cholangiocarcinoma and Gallbladder Cancer Studies
  • Lung Cancer Treatments and Mutations
  • Boron Compounds in Chemistry
  • Prostate Cancer Diagnosis and Treatment
  • Cancer Mechanisms and Therapy
  • Nanoplatforms for cancer theranostics
  • Dysphagia Assessment and Management

Chiba University
2011-2024

National Institutes for Quantum Science and Technology
2017-2023

Chiba Hospital
2020-2021

Chiba Prefectural Sawara High School
2012

Numazu City Hospital
2010-2011

Kansai Medical University
2005-2009

T1 esophageal squamous cell carcinoma (ESCC) has a low, but still present, risk of lymph node (LN) metastasis. Endoscopic mucosal resection (EMR) or endoscopic submucosal dissection (ESD) is often applied for ESCC. To achieve successful treatment by EMR/ESD, the LN metastases, recurrence, and hematological recurrence need to be better understood. The aim this study was determine precise metastasis in ESCC.We divided 295 patients with ESCC who underwent surgery and/or ESD/EMR into 6...

10.1097/sla.0b013e31827017fc article EN Annals of Surgery 2012-10-30

FSCN1 and matrix metalloproteinase 14 (MMP14) are both invadopodia-related proteins. We herein elucidate the tumourigenicity of these proteins identify novel therapeutic agents in esophageal squamous cell carcinoma (ESCC). MMP14 were evaluated by immunohistochemistry quantitative PCR, microRNA (miR)-133a was also PCR surgical ESCC specimens. The roles FSCN1, miR-133a established cells. expression or an independent poor prognostic factor according to a multivariate analysis...

10.1038/bjc.2013.676 article EN cc-by-nc-sa British Journal of Cancer 2013-11-05

High linear energy transfer (LET) radiation carbon-ion radiotherapy (C-ion RT) is one of the most promising modalities for treating unresectable primary pancreatic cancers. However, how LET contributes to a therapeutic effect not clear. To assess whether there an enhanced high on tumour control, we aimed determine impact dose-averaged local control (LC) tumours.A retrospective analysis 18 patients with carcinomas treated definitive C-ion RT concurrent chemotherapy in 2013 was conducted. The...

10.1016/j.ctro.2019.11.002 article EN cc-by-nc-nd Clinical and Translational Radiation Oncology 2019-11-26

The aim of this study was to determine whether histone acetylation regulates tumor suppressive microRNAs (miRNAs) in esophageal squamous cell carcinoma (ESCC) and identify genes which are regulated by these miRNAs. We identified a miRNA that highly upregulated an ESCC line cyclic hydroxamic acid-containing peptide 31 (CHAP31), one the deacetylase inhibitors (HDACIs), using array analysis. miR-375 strongly CHAP31 treatment line. expression levels most miRNA, were analyzed quantitative...

10.3892/ijo.2012.1537 article EN cc-by International Journal of Oncology 2012-06-28

The expression of microRNA-203 (miR-203) in esophageal squamous cell carcinoma (ESCC) tissues is remarkably lower than that non‑ESCC tissues. We investigated how miR-203 could influence the development ESCC cells. Our analyses revealed inhibited migration and invasion Genome-wide gene data target site inhibition assays showed appears to directly regulate LIM SH3 protein 1 (LASP1). knockdown LASP1 resulted results suggest its LASP1, may be associated with progression ESCC. In clinical...

10.3892/ijo.2012.1614 article EN cc-by International Journal of Oncology 2012-08-30

Abstract There are no clinical reports of long‐term follow‐up after carbon‐ion radiotherapy (CIRT) using a dose 51.6 Gy (relative biological effectiveness [RBE]) in 12 fractions for localized prostate cancer, or comparison outcomes between passive and scanning beam irradiation. A total 256 patients with cancer who received CIRT at (RBE) two different delivery techniques (passive [ n = 45] 211]), were followed more than 1 year, analyzed. The biochemical relapse‐free (bRF) rate was defined by...

10.1111/cas.15019 article EN Cancer Science 2021-06-09

Cyclooxygenase-2 (COX-2) is a key enzyme of prostaglandin (PG) synthesis that has been demonstrated to be overexpressed in several types cancers. The function COX-2 tumor progression recently elucidated. In tumors which overexpressed, the antitumor effects are suppressed. We examined celecoxib, inhibitor, enhancing chemotherapy and radiotherapy for esophageal squamous cell carcinoma (ESCC) by reducing activity. used human lines TE2 T.Tn treated with celecoxib 5-FU/radiation, after viability...

10.3892/ijo.2014.2300 article EN International Journal of Oncology 2014-02-14

Background: The purpose of the present study was to evaluate efficacy and safety single-fraction carbon-ion radiotherapy (CIRT) in patients with non-small cell lung cancer. Methods: Patients histologically confirmed cancer, stage T1-2N0M0, treated CIRT (50Gy (relative biological effectiveness)) between June 2011 April 2016 were identified our database retrospectively analyzed. Toxicity evaluated using Common Terminology Criteria for Adverse Events version 4.0. Results: included 57 patients,...

10.3390/cancers13010112 article EN Cancers 2020-12-31

This study aimed to assess the safety and efficacy of carbon-ion radiotherapy (CIRT) for salvage previously X-ray-irradiated (XRT) locally recurrent rectal cancer (LRRC).Between September 2005 December 2017, 77 patients with LRRC were treated CIRT re-irradiation. All had received prior XRT a median dose 50.0 Gy (range 20-74 Gy), principally neoadjuvant or adjuvant recurrence prophylaxis in 34 43 patients. The total 70.4 (RBE) (gray relative biologic effectiveness) was administered 16 fixed...

10.1245/s10434-021-10876-4 article EN cc-by Annals of Surgical Oncology 2021-10-18

Abstract Background The correlation between the number of pathologic metastatic LNs in patients with esophageal squamous cell carcinoma (ESCC) after neoadjuvant chemoradiotherapy (NACRT) and surgical outcome has rarely been reported. We evaluated lymph nodes (LNs) ESCC NACRT. Methods Eighty‐eight who underwent NACRT followed by surgery were evaluated. clinical response was specimens primary tumor resected analyzed clinicopathologically. Results Fewer associated better survival. According to...

10.1002/jso.23007 article EN Journal of Surgical Oncology 2011-12-12

Prognosis is usually grim for those with liver metastasis from colorectal cancer ( CRC ) who cannot receive resection. Radiation therapy can be an option unsuitable resection, carbon ion radiotherapy CIRT being more effective and less toxic than X‐ray due to its physio‐biological characteristics. The objective of this study identify the optimal dose single fraction metastasis. Thirty‐one patients were enrolled in present study. Twenty‐nine received a single‐fraction , escalating 36 Gy RBE 5%...

10.1111/cas.13872 article EN Cancer Science 2018-11-12

Carbon ion beams have several physical and biological advantages compared with conventional radiation for cancer therapy. The objective of this study is to evaluate the safety effectiveness 2-fraction carbon therapy (CIRT) in patients hepatocellular carcinoma (HCC).Between December 2008 March 2013, 57 localized HCC were treated CIRT at a total dose 45 Gy (relative effectiveness) 2 fractions retrospectively analyzed after long-term observation. main endpoints treatment-related toxicity local...

10.1016/j.adro.2019.09.007 article EN cc-by-nc-nd Advances in Radiation Oncology 2019-09-27

Background The safety and effectiveness of carbon‐ion radiotherapy (CIRT) for isolated para‐aortic lymph node (PALN) metastasis was evaluated retrospectively. Methods CIRT PALN from CRC performed in 34 cases June 2006 to August 2015 our institute. A median dose 52.8 Gy(RBE) (range, 48‐52.8 Gy(RBE)) delivered with a daily 4.4 4.0‐4.4 Gy(RBE)). Results follow‐up duration all patients 24.4 months 7‐82.8 months). There were 13 (38.2%) who achieved complete response after treatment. local control...

10.1002/jso.24757 article EN Journal of Surgical Oncology 2017-07-20

Patients who receive carbon-ion radiotherapy (C-ion RT) for primary pancreatic cancer may experience locoregional recurrence; however, the treatment options such patients are limited. We aimed to investigate feasibility and efficacy of re-irradiation with experienced recurrence after initial C-ion RT.Twenty-one recurrent underwent repeat RT between December 2010 November 2016 at our institute were retrospectively evaluated. The sites post-initial failure in-field central in 16 (76.2%)...

10.1016/j.ctro.2020.10.007 article EN cc-by-nc-nd Clinical and Translational Radiation Oncology 2020-11-06

Introduction Photodynamic therapy (PDT) is a less invasive option for cancer treatment that has evolved through recent developments in nanotechnology. We have designed and synthesized novel liposome system includes an indocyanine green (ICG) derivative, ICG-C18, its bilayer. In addition to use as optical imager visualize blood, lymphatic, bile flow, ICG also been used sensitizer. the present report, we evaluate of our system, LP-ICG-C18, PDT squamous cell carcinoma autologous murine model....

10.1371/journal.pone.0122849 article EN cc-by PLoS ONE 2015-04-07
Coming Soon ...